The EuroEspes International Centre for Neuroscience and Genomic Medicine, with more than 30 years of experience, is a world pioneer in the implementation of Personalised Medicine based on knowledge of the Human Genome.
Since our launch in 1991, we have invested in research and development to accelerate the practical application of scientific advances for the benefit of people's health.
The EuroEspes Medical Centre offers its users Genomic Medicine services for predictive, diagnostic and therapeutic purposes.
The major advances that genomic medicine offers to medical specialties are confined to three areas:
Less than 10% of the primary causes of disease in humans are currently known. Structural and functional genomics, epigenetics, transcriptomics, and metabolomics are modern-day, cutting-edge scientific disciplines that now allow a more precise approach to understanding the causes of disease. If we know the endogenous and exogenous factors that cause a disease, we can diagnose it accurately and treat it in a personalised way.
Most diseases can affect the human species at any age, but especially those that account for 80% of the world's morbidity and mortality (cardiovascular diseases, cancer, brain disorders), progressively destroy our bodies decades before the manifestation of symptoms.
Genomic medicine aims to implement the use of biomarkers that help predict the risk of disease many years before it manifests itself.
This Predictive Diagnosis is the only one that will allow us to implement Personalised Prevention Programmes to delay the onset of a disease or to avoid it, when possible. At the same time, Genomic Medicine has Biomarkers for Early Diagnosis, in order to be able to treat each patient as quickly and efficiently as possible.
One of the great advances in Genomic Medicine is the implementation of Personalised Treatment, adapted to the genetic profile of each patient.
No one medicine works the same for all patients.
The actual efficacy of most drugs is 20-30%; in more than 60-70% of cases, drugs are ineffective or toxic. Using pharmacogenomics, it is possible to optimise the use of medicines, improving the efficacy and reducing the toxicity of more than 60-80% of commonly used drugs in any medical speciality.
The EuroEspes Medical Centre offers its users the Smart Pharmacogenetics Card, through which everyone has the possibility of knowing, together with their prescribing doctor, the medicines they can take and those they should avoid.
Among our priorities is the search for efficient solutions to the serious problem of dementia (Alzheimer's disease, vascular dementia), stroke and other degenerative problems of the nervous system, such as Parkinson's disease, as well as responding to neuropsychiatric diseases and other prevalent diseases, such as cardiovascular diseases and cancer.